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For highly lipophilic drugs, passage into the intestinal lymphatic system rather than portal 
vein following oral administration may represent a major alternative route of delivery 
into the general circulation. Increasing intestinal lymphatic transport provides an 
effective strategy to improve oral bioavailability when hepatic first-pass metabolism is a 
major rate-limiting step hampering access to the systemic circulation after oral dosing. 
The transfer of orally administered, highly lipid-soluble drugs to the lymphatic system is 
mediated by their association with chylomicrons, large intestinal lipoproteins which are 
assembled in the enterocytes in the presence of long-chain triglyceride or long-chain fatty 
acids. Due to its very high lipophilicity, cannabidiol (CBD) has physicochemical features 
(e.g. logP=6.3) consistent with an oral absorption mediated at least in part by transport 
via the intestinal lymphatic system. CBD also undergoes extensive first-pass hepatic 
metabolism. Formulation changes favoring diversion of orally absorbed CBD from the 
portal to the lymphatic circulation pathway can result in reduced first-pass liver 
metabolism, enhanced oral bioavailability and reduced intra- and inter-subject variability 
in systemic exposure. In this manuscript we discuss: (i) evidence for CBD undergoing 
hepatic first-pass liver metabolism and lymphatic absorption to a clinically important 
extent, (ii) the potential interplay between improved oral absorption, diversion of orally 
absorbed drug to the lymphatic system, and magnitude of pre-systemic elimination in the 
liver; and (iii) strategies by which innovative chemical and/or pharmaceutical delivery 






 Cannabidiol (CBD) has low and variable oral bioavailability (approximately 6% on 
average), due to incomplete gastrointestinal absorption and extensive pre-systemic 
elimination in the liver. 
 Because of its very high lipophilicity, CBD has physicochemical features (e.g. 
logP=6. 3) consistent with absorption being mediated at least in part by transport via 
the intestinal lymphatic system.  
 Innovative products/formulations that improve CBD solubilization in the 
gastrointestinal tract and re-route orally absorbed CBD from the portal to the 
lymphatic circulation can reduced the extent of hepatic first-pass metabolism, 
enhance oral bioavailability and reduce intra- and inter-subject variability in systemic 
exposure. 
 The potential interplay between improved oral absorption, diversion of orally 
absorbed drug to the lymphatic system, and magnitude of hepatic-first pass effect 
should be considered in the design of new chemical and/or pharmaceutical delivery 















Absorption from the gastrointestinal tract into the portal vein represents the best 
characterized pathway by which orally administered drugs enter the systemic circulation. 
Although the intestine also has a rich network of lymphatic vessels, the flow rate of 
intestinal lymph fluid is 500- to 100-fold lower than the blood flow through the portal 
vein, and absorption through the lymphatic system is negligible for the majority of small 
molecule drugs [1]. However, increasing evidence indicates that, for highly-lipid soluble 
drugs with low water solubility and a high affinity for lipoproteins, passage into the 
intestinal lymphatic system may represent a major alternative route of delivery into the 
general circulation [2]. In contrast to portal blood, mesenteric lymph flows directly from 
the mesenteric duct to the thoracic duct, and from there to the systemic circulation at the 
junction of the left subclavian and jugular veins, without passing through the liver at first 
pass. Therefore, increasing intestinal lymphatic transport may provide an effective 
strategy to improve oral bioavailability when hepatic first-pass metabolism is a major 
rate-limiting step hampering access to the systemic circulation.  
The transfer of  highly-lipid soluble orally administered drugs to the lymphatic system is 
mediated by their association with chylomicrons, large intestinal lipoproteins which are 
assembled in the enterocytes in the presence of long-chain triglyceride or long-chain fatty 
acids [3]. The availability of a source of lipids for lipoprotein formation represents a 
mechanism by which lipid-based formulations or concurrent intake of a high-fat meal can 
enhance the oral bioavailability of drugs with low water solubility [4]. Additionally, 
lipid-rich food and lipid excipients can facilitate solubilization of drug molecules in the 
intestinal lumen, thereby providing an additional mechanism to improve oral 
bioavailability [2]. 
Due to its very low water solubility (12.6 mg/L) and high lipophilicity as indicated by a 
logP of 6.3, the antiseizure medication cannabidiol (CBD) has physicochemical features 
consistent with potential absorption via the intestinal lymphatic system. CBD also 
undergoes extensive hepatic metabolism [5] and shows negligible renal excretion [6], 
which classifies it as a BCS/BDCCS Class 2 drug (poorly water-soluble, highly 
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permeable, highly metabolized drug) according to the Biopharmaceutics Classification 
System (BCS) and the Biopharmaceutics Drug Disposition Classification System 
(BDDCS), respectively [7]. Importantly, CBD shows a high intra- and inter-subject  
pharmacokinetic variability [8, 9]. This is largely related to its very low oral 
bioavailability in humans,  which is due to incomplete absorption as well as extensive 
pre-systemic metabolism in the liver [5, 7]. If CBD is at least in part susceptible to uptake 
by the lymphatic intestinal system, the implications in terms of biopharmaceutical 
optimization could be important. In fact, formulation changes favoring diversion of orally 
absorbed CBD from the portal to the lymphatic pathway could result in reduced hepatic 
first-pass metabolism and enhanced oral bioavailability. Improving CBD’s oral 
bioavailability, in turn, would be expected to  reduce intra- and inter-subject variability in 
systemic exposure[7, 10].  In a study of bioequivalence data for 65 immediate-release 
drugs, for example, the coefficient of variation (%CV) for intra-subject variability in 
plasma exposure has been been found to decrease from 30─65% when oral 
bioavailability is below 5% to less than 20% when bioavailability is above 80% [10]. 
Therefore, the advantages of a novel formulation of CBD with improved bioavailability 
in minimizing variability in clinical response could be considerable. 
The purpose of this article is to: (i) review the evidence for CBD undergoing extensive 
first-pass metabolism, and its susceptibility to lymphatic absorption; (ii) assess the 
potential interplay between improved oral absorption, diversion of orally absorbed drug 
to the lymphatic system, and magnitude of pre-systemic elimination in the liver; and (iii) 
discuss strategies by which innovative chemical and/or pharmaceutical delivery systems 
of CBD with improved bioavailability characteristics could be developed.     
 
CBD as a drug with a high hepatic extraction ratio 
The absolute bioavailability (F) of CBD in humans after oral dosing under fasting 
conditions is generally reported to be about 6% [5, 11-15], as recently confirmed in a 
formal pharmacokinetic study conducted by the manufacturer of the FDA-approved 
formulation [Morrison G, personal communication, April 2020]. Its clearance (CL) as 
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determined in the only published study in humans, in which deuterium-labeled drug (20 
mg) was administered intravenously to 5 healthy subjects, has been estimated at 1240 ± 
240 mL/min (mean ± SD, range 960-1560 mL/min) [15]. The latter value, however, may 
represent an overestimate because calculated based on AUC values calculated up to 48 
hours (2 subjects) and 72 hours (3 subjects), respectively.  Assuming that CBD blood-to-
plasma ratio is about 1, as in the case of tetrahydrocannabinol (THC) [13, 16, 17], and 
that CBD elimination occurs primarily in the liver [12, 13], a CL value of 74 L/h 
corresponds to a liver extraction ratio (E) in the order of 65-70% [13, 15, 17, 18]. 
Based on the above measures, CBD behaves pharmacokinetically as a drug with a high 
liver extraction ratio (E), which implies that its total body (metabolic) clearance is 
predicted to be affected more by changes in liver blood flow (Q) than by induction or 
inhibition of drug metabolizing enzymes [18, 19]. According to the well-stirred model of 
hepatic elimination, in which instantaneous and complete mixing of circulating blood is 
assumed to occur within the liver, F can be estimated by using equation 1: 
 
F = Ff FGI(1-E) = Ff FGIQ/(Q + fu CLint)                                                                 (1) 
 
where Ff, FGI, CLint and fu represent the fraction of the CBD dose that is neither lost in the 
feces nor decomposed in the lumen, the fraction of the dose escaping gastrointestinal 
first-pass metabolism, the hepatic intrinsic clearance of CBD and the unbound fraction of 
CBD in blood, respectively [18, 19]. Equation 1 assumes that E is concentration 
independent (e.g., that saturation of first-pass metabolism does not occur during the 
absorptive phase), and does not take into consideration potential absorption through 
intestinal lymphatic vessels, a possibility that will be discussed in the subsequent part of 
this article.  
CBD is negligibly excreted unchanged in urine [20], and its systemic exposure is 
increased by more than 5-fold in patients with severe hepatic impairment, an observation 
suggestive of metabolism taking place primarily in the liver [21]. Therefore, it is 
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reasonable to assume that CBD undergoes minimal intestinal first-pass metabolic loss 
upon oral administration, i.e., that FGI approaches 1. Thus, based on equation 1, changes 
in CBD intrinsic clearance (CLint) in the liver due to induction or inhibition of its 
metabolism would be expected to result in prominent changes in bioavailability after oral 
administration. On the other hand, changes in CBD CLint would be expected to cause 
more modest changes in systemic exposure after parenteral administration, as is the case 
for drugs subject to high, flow-dependent hepatic extraction [18, 19, 22, 23]. 
 
Lymphatic absorption of CBD 
As discussed in the introduction of this article, orally administered lipophilic drugs may 
gain access to the systemic circulation via the intestinal lymphatics following 
incorporation into large lipoproteins such as chylomicrons [24-26]. In fact, chylomicrons 
are too large for direct passage to the blood capillaries, and are dependent on transfer to 
the lymphatic system for their absorption together with the incorporated lipophilic drug 
[27-29]. The passage of drugs to the intestinal lymph seems to be enhanced by their co-
administration with long-chain lipids preferentially to short- and medium-chain lipids 
[30], and is influenced by the physicochemical characteristics of the drug, primarily a 
distribution coefficient (logD) at pH 7.4 >5 and a solubility in long-chain triglycerides 
>50 mg/g [31, 32]. Marketed oral formulations of THC (Marinol®) and CBD 
(Epidiolex®) contain sesame oil, which is mostly composed of long-chain triglycerides. It 
has been stated that the rationale for adding sesame oil to these formulations is to 
dissolve the lipid-soluble cannabinoids [29].  
In a carefully conducted study in a rat model, Zgair et al [29] found that plasma exposure 
to orally administered CBD and THC increased by 2.5-fold and 3-fold, respectively, 
when the compounds were co-administered with lipids compared with intake without 
lipids [29]. Following in vitro lipolysis, more than 30% of THC and CBD were found to 
be distributed into the micellar fraction, indicating that at least one third of an oral dose 
could be absorbed if these cannabinoids are co-administered with lipids. Further 
experiments confirmed the association of CBD with chylomicrons, suggesting that 
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incorporation of pharmaceutical lipid excipients in the CBD oral dosage form could 
increase substantially its oral bioavailability by rerouting partly its absorption from the 
portal vein to the intestinal lymphatic system. The amount of lipids present in a high-fat 
meal is sufficient to activate CBD intestinal lymphatic transport and to increase its oral 
bioavailability [29]. The lymphatic transport of CBD was confirmed by the same authors 
in a subsequent study in which CBD levels were monitored directly in mesenteric lymph 
[33]. 
Measurement of drug levels in the intestinal lymph requires complex invasive procedures 
which have been done in humans only under exceptional circumstances [34]. However, 
the physicochemical characteristics of CBD, coupled with the evidence from the animal 
studies discussed above, are fully consistent with the possibility of CBD undergoing 
intestinal lymphatic transport also in humans. The observation that CBD bioavailability 
increases four-fold when the drug is taken together with a high fat-meal [8, 9, 35] is also 
fully compatible with a lipid-driven enhancement of intestinal lymphatic transport, 
similarly to findings from animal studies [29, 33]. 
In this regard, a particularly valuable contribution, which is relevant to understanding the 
determinants of CBD bioavailability in humans and experimental animals, is an elegant 
study conducted with another cannabinoid drug, the CB1 and CB2 receptor agonist 
CRA13 (SAB-378) [36]. By conducting parallel experiments in humans and in lymph-
cannulated dogs, Trevaskis and coworkers demonstrated that enhancement of the oral 
bioavailability of CRA13 when given with a high-fat meal does not result from increased 
absorption per se but from a significant increase in its transport into the lymphatic system 
and consequent reduction in its first-pass metabolism in the liver [36]. In fact, the poor 
absolute bioavailability of CRA13 in fasted dogs (8-20%) was not due to failure to pass 
through the gastrointestinal epithelium, but to a large hepatic first-pass effect, which 
could be bypassed partly when CRA13 was administered with food and its absorption 
was diverted to the lymphatic pathway. The physicochemical properties of CRA13 (logP 
6.9, water solubility 19 mg/L, molecular weight 369) are similar to those of CBD (logP 
6.3, water solubility 13 mg/L, molecular weight 314)[37], suggesting that these findings 




The interplay between CBD oral absorption, lymphatic transport and liver first-
pass metabolism 
For a drug like CBD which is highly likely to be taken up at least in part into intestinal 
lymphatic vessels,  the fraction of the dose absorbed from the gastrointestinal tract can be 
defined as the sum of the fraction  absorbed via the lymphatic (flymph) system and thus not 
exposed to liver first-pass effect, and the fraction absorbed via the portal system (fportal) 
[27]. Incorporating flymph and the portal system fportal into equation 1 yields equation 2: 
 
F = Ff FGI [flymph + fportal(1-E)] = Ff FGI [flymph+ fportalQ/(Q + fu CLint) ]                           (2)                                                    
 
Intra- and inter-subject variability in F results from the many factors that influence each 
of the key  elements of equation 2. For example,  Ff is dependent not only on the 
properties of the drug and the formulation used, but also on the presence and composition 
of any co-administered food, rate of gastrointestinal motility, activity of transporter 
systems, and drug-drug interactions within the gastrointestinal lumen [38, 39], whereas 
CLint is influenced by factors that affect the activity of drug transporters and hepatic drug 
metabolizing enzymes, including age, genetic polymorphisms, endocrine influences, 
enzyme induction, enzyme inhibition, and disease states [39, 40]. With respect 
specifically to flymph, this is influenced primarily by a drug’s ability to associate with 
chylomicrons in the enterocyte, which in turn is dependent on the drug’s physico-
chemical properties, availability of a source of lipids (especially long-chain lipids) and 
characteristics of the formulation [25, 32].  By stimulating the production of lymph, 
dietary or formulation-based lipids can also increase mesenteric lymphatic flow [41], 
although lymph flow per se is likely to affect rate more than extent of lymphatic 
absorption.  
Following oral dosing, most small-molecule drugs are absorbed via the portal vein (i.e. 
fportal > flymph), which for drugs with a high hepatic extraction (E) results to extensive pre-
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systemic elimination. By diverting the absorbed drug from the portal to the lymphatic 
transport, pre-systemic elimination can be minimized and oral bioavailability can be 
enhanced [32]. The relative contribution of lymphatic (flymph) and portal pathways (fportal) 
to overall absorption can be formulation-dependent, and a successful formulation 
targeting the lymphatic circulation could mitigate CBD susceptibility to hepatic first-pass 
metabolism.   
In a series of simulations, Brocks and Davis [27] have shown that the impact of lymphatic 
absorption on systemic drug exposure is influenced by the extent by which a drug is 
removed from the blood flowing through the liver [27]. Drugs with low E (<30%) are not 
likely to have any systemic bioavailability advantage from diverting their gastrointestinal 
absorption from the portal to the lymphatic system. As depicted in equations 1 and 2, for 
drugs with low E values, even a relatively large percent change in E will have a 
negligible effect on oral bioavailability, because these drugs are subject to little or no 
hepatic first-pass effect. A diversion from portal to lymphatic absorption can impact oral 
bioavailability only for drugs with E>30%, whose systemic exposure is influenced by 
hepatic first-pass metabolism. The higher is a drug's E value, the greater is the potential 
to increase its oral bioavailability through a formulation-dependent enhancement of 
lymphatic absorption.  
Because CBD has a high E value (estimated at 65-70%), it is an attractive candidate for 
the development of innovative formulations enhancing its intestinal lymphatic absorption. 
An oral formulation that will divert CBD absorption from the portal to the lymphatic 
pathway (i.e., decrease fportal and increase flymph in equation 2) could exert a large effect on 
the oral bioavailability of CBD. As discussed above, the average absolute oral 
bioavailability of CBD is about 6% after intake under fasting conditions [5, 7], and 
increases 4-fold when the drug is co-administered with a lipid-rich meal [8, 9, 35], 
probably due at least in part to facilitation of lymphatic transport [29]. An innovative 
formulation which is as effective as a high-fat meal in improving CBD dissolution in the 
intestinal fluids and in diverting CBD absorption from the portal to the lymphatic system 
would be expected not only to provide a similar bioavailability enhancement, but also to 
reduce intra- and inter-individual variability in systemic exposure and to minimize the 
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magnitude of drug interactions affecting presystemic CBD metabolism in the liver, and 
the adverse effects that might arise from such interactions. Even if such an innovative 
formulation were still subject to an interaction with food, that interaction could be 
avoided by administering the product away from meal times. The overall result would be 
a more consistent bioavailability than that obtained by co-administration with food, 
whose effects on CBD pharmacokinetics are highly variable in relation to the 
composition of the meal [8]. A formulation causing a diversion of CBD uptake into the 
lymphatic vessels to a greater extent than that achieved with a high-fat meal could 
increase CBD bioavailability further, potentially above the 35% ceiling which based on 
hepatic clearance estimates applies if entry into the systemic circulation only occurs via 
the portal system. It should be noted that incorporation of a drug into lipoproteins may 
affect not only the pathways by which the drug reaches the systemic formulation, but also 
its tissue distribution and rate of hepatic metabolism [1]. These potential pharmacokinetic 
changes will require careful exploration, as they may impact on the extent and time 
course of pharmacological activity. 
 
Potential strategies to facilitate lymphatic absorption  
Potential strategies by which innovative lymphatic system-targeted CBD formulations 
with improved oral bioavailability can be developed include (i) use of chemical drug 
delivery systems or prodrugs and (ii) use of pharmaceutical drug delivery systems.  
The former approach has been utilized to design prodrugs of testosterone that are based 
on a glyceride template that mimics the digestion, re-esterification and lymphatic 
transport pathways of dietary triglycerides [42]. In these experiments, testosterone was 
used as a model drug for substances undergoing extensive hepatic first-pass metabolism. 
The mean absolute oral bioavailability (± SD) of testosterone (F) and of a commercially-
available lipophilic prodrug testosterone undecanoate in humans is only 3.6 ± 2.5% and 
6.8 ± 3.3%, respectively [43]. The bioavailability of the undecanoate is further limited by 
intestinal metabolism, even though some lymphatic absorption does occur, as shown by a 
study done in 4 patients who had a thoracic duct catheter inserted after neck dissection 
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surgery [34]. The glyceride-mimetic prodrugs designed to improve testosterone 
bioavailability were constructed by bridging testosterone and the alkyl-substituted 
glyceride moiety (e.g. 1,3-diacylglycreol oxidized to its acid-terminated triglyceride) with 
a five-carbon self-immolative spacer to which a linker was inserted [42]. The entire 
glyceride-mimetic moiety was conjugated to testosterone via an esteric bond. Following 
oral administration to rats, the glyceride-mimetic prodrugs were hydrolyzed to 
testosterone yielding a plasma exposure that was significantly higher than that obtained 
after oral dosing of testosterone and the undecanoate. The oral bioavailability of 
testosterone increased with increasing cumulative extent of lymphatic transport, which 
was 0% for testosterone, 1.9% for testosterone undecanoate and 9.5─28% for the 
glyceride-mimetic prodrugs [42]. The testosterone undecanoate formulation was a 
solution in oleic acid encapsulated in a soft gelatin capsule. This shows that a 
combination of a lipophilic prodrug in oily solution that is mainly absorbed by lymphatic 
transport is not sufficient to increase testosterone’s F value above 6.8%. In order to obtain 
an F>10% there was a need to design glyceride-mimetic prodrugs with a self-immolative 
spacer to that includes a linker as described above [42]. 
Another lymphatic system-targeted approach using lipophilic-activated ester prodrugs 
was applied by Lee at al. [28] to deliver bexarotene and retinoic acid to the intestinal 
lymphatic vessels. A range of carboxylic ester prodrugs of bexarotene were designed, and 
all esters showed improved association with chylomicrons, which indicated an improved 
potential for delivery to the intestinal lymphatic system. The rate at which the prodrugs 
were converted to bexarotene in lymph fluid was the primary determinant of their 
delivery to the intestinal lymphatic system. Activated ester prodrugs were prepared to 
enhance the conversion rate in comparison to simple alkyl ester prodrugs [28]. Because 
CBD has lipophilic properties similar to those of testosterone and bexarotene, it could be 
a suitable candidate for utilization of the prodrug approach.   
As mentioned above, an alternative approach to develop a lymphatic-system targeted 
product involves the use of pharmaceutical delivery systems which incorporate dietary 
fats and pharmaceutical lipid excipients to mimic the absorptive milieu associated with  
ingestion of a high-fat meal [27, 29, 33]. By using this approach, Zgair et al. [29] 
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investigated the effect of orally administered lipids on the exposure of THC and CBD, 
and concluded that co-administration with dietary lipids or pharmaceutical lipid 
excipients diverting absorption to the lymphatic vessels has the potential to increase 
substantially the oral bioavailability of both cannabinoids [29].  In another study, Liao et 
al. [44] prepared a complex of the flavonoid baicalein with phospholipids and 
incorporated it into a self-microemulsifying drug delivery system (SMEDDS) with the 
aim of improving baicalein’s oral bioavailability by enhancing its lymphatic absorption. 
In vivo experiments in rats demonstrated that the bioavailability of SMEDDS-
incorporated baicalein was increased by 342.5% compared with the bioavailability of 
baicalein given as such. When the baicalein-phospholipid complex was incorporated into 
a SMEDDS, the bioavailability of the flavonoid (relative to baicalein administered as 
such) increased to 448.7%. Lymphatic transport studies revealed that after dosing with 
baicalein as such, 81.2% of the orally absorbed flavonoid entered the circulation directly 
through the portal vein, and approximately 18.8% was taken up by the lymphatic system. 
Incorporation into a SMEDDS increased the proportion taken up by the lymphatic system 
from 18.8% to 56.2%, and the increase was even greater (to 70.2%) when the SMEDDS-
incorporated baicalein-phospholipid complex was administered. Therefore, the self-
microemulsion not only improved significantly the oral bioavailability of baicalein, but 
also increased its extent of absorption via the lymphatic system, the effect being more 
prominent when the flavonoid was given as phospholipid complex [44]. The potential 
value of approaches based on use of phosphospholipid complexes combined with a self-
emulsifying system is further illustrated by studies with silybin, a water-insoluble 
flavonolignan which is the main active component of silymarin, an extract of the milk 
thistle plant (Silybum marianum). Tong et al. [45] prepared a silybin–phospholipid 
complex, which was then encapsulated into a self-nanoemulsifying drug delivery system 
(SNEDDS). Using a dynamic in vitro digestion model, the lipolysis of the silybin–
phospholipid complex in the SNEDDS was found to be related mainly to the properties of 
the lipid excipients. Experiments with an in situ perfusion model showed that the 
intestinal absorption of silybin was highest for the SNEDDS-incorporated silybin–
phospholipid complex, intermediate for the silybin–phospholipid complex alone, and 
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lowest for silybin itself. The extent of lymphatic transport for the silybin–phospholipid 
complex and for the SNEDDS-incorporated silybin–phospholipid complex was 12.2- and 
22.7-fold higher, respectively, than that for silybin [45]. In lymph duct cannulated rats, 
the relative bioavailability of the silybin–phospholipid complex was 12.7 times as high as 
that of silybin, while the bioavailability of the SNEDDS-incorporated silybin–
phospholipid complex was 18 times as high as that of silybin. Interestingly, an earlier 
study in humans demonstrated that administration of silybin in the form of a complex 
with phosphatidylcholine resulted in a 4.6-fold increase in silybin oral bioavailability 
relative to silybin administered as silymarin [46]. The increase in silybin bioavailability 
obtained with the phosphatidylcholine complex compared with sylibin administered as 
silymarin was probably markedly underestimated, because the assay used did not 
differentiate silybin from isosilybin, another component of silymarin [47]. Whether the 
improved bioavailability of silybin given as a complex with phosphatidylcholine in 
humans is related at least in part to enhanced lymphatic absorption and avoidance of 
hepatic first-pass metabolism is not known, but this possibility would be consistent with 
the results of animal studies [45]. Importantly, the similar low-water solubility of CBD 
(12.6 mg/mL) and silybin (9.8 mg/mL) suggests that a pharmaceutical approach based on 
utilization of a phospholipid complex incorporated into SNEDDS [45] could be applied 
successfully also to CBD. In fact, the interest in developing novel self-emulsifying 
delivery systems for CBD, including SNEDDS, is growing, and results of early 
pharmacokinetic studies appear to be promising [48-50].    
Whether any of the strategies described above would succeed in enhancing the oral 
bioavailability of CBD up to (or above) the level (about 25%) observed with the currently 
available FDA-approved formulation taken together with a high-fat meal remains to be 
determined. However, since hepatic first-pass metabolism is the main factor limiting 
CBD’s oral bioavailability (F), even a more modest bioavailability enhancement would 
be valuable if it is associated with reduced intra- and inter-individual variability, and less 
susceptibility to food effects. Of note, such an enhancement is unlikely to be achieved by 
increasing the amount of sesame oil in the current FDA-approved formulation (e.g., using 
a less concentrated formulation) because the large volume required would adversely 
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affect palatability and compliance, and entail an excessive caloric intake. Attractive 
development strategies to consider in pharmaceutical delivery systems may include use 
of pre-digested lipids, incorporation in the formulation of various surfactants,  and use of 
optimized mixtures of short, medium and long-chain triglyceride or fatty acids. In 
particular, use of  pre-digested lipid formulations, containing fatty acids and 
monoglycerides instead of triglycerides, could remove intra- and inter-subject variability 
related to differences in the digestion of lipids in the gastrointestinal tract [51].  
In addition to diverting absorption from the portal to the lymphatic system, alternative 
strategies to improve the oral bioavailability of CBD are being considered. An interesting 
approach, that can be combined with lymphatic-targeted strategies, involves 
incorporation in the formulation of  compounds which may enhance oral bioavailability 
by inhibiting CBD drug metabolizing enzymes and thereby reducing the extent of its 
first-pass effect [52]. Preliminary encouraging results have been obtained by 
incorporating piperine into a SNEDDS-based delivery system [52, 53], but further studies 
are required to determine the actual potential of this approach in terms of 
pharmacokinetic performance and clinical safety. 
 
Final considerations and conclusions 
The evidence discussed in this article indicates that CBD shows suboptimal 
pharmacokinetics due its low solubility in intestinal contents, incomplete oral absorption 
and prominent fist-pass effect in the liver. These factors result in a large intra- and inter-
subject variability in oral bioavailability, which is further compounded by pronounced 
food effects [8, 9, 35]. Because a large variability in CBD plasma concentrations could 
adversely affect clinical response, there is scope for developing innovative chemical 
and/or pharmaceutical delivery systems associated with enhanced and more consistent 
bioavailability. Potential breakthroughs in addressing this goal may come from evidence 
that CBD has physicochemical and pharmacokinetic characteristics compatible with 
absorption taking place partly through the lymphatic system, as confirmed by animal 
studies. Delivery systems designed to enhance CBD solubilization in the intestine and 
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divert absorption from the portal to the lymphatic system could improve CBD 
bioavailability substantially. Irrespective of the enhancement in systemic exposure 
achieved, such delivery systems could also reduce markedly pharmacokinetic variability, 
particularly if these systems succeed in attenuating bioavailability changes in relation to 
food intake [8, 9, 35] and meal composition [8]. When developing innovative CBD 
delivery systems, consideration should also be given to existing concerns about the 
burden of allergies associated with sesame oil [54], the main excipient present in the 
current FDA-approved CBD formulation. This implies that novel CBD delivery systems, 
in addition to benefits derived from greater and more consistent bioavailability, could 
also be associated with advantages in terms of improved tolerability and safety. 
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